2 results
Approved WMOCompleted
Primary Objective- To demonstrate dose proportionality between 1 mg and 5 mg of PedPRM (Neurim Pharmaceuticals Ltd.) following a single oral dose in healthy male and female volunteers (treatment A and C), under fed conditions.Secondary Objectives-…
Approved WMOCompleted
Primary Objective: To prove the hypothesis that Intradiscal Methylene blue is capable of longer pain reduction and better global perceived effect in patients suffering from chronic axial low back pain from discogenic origin then a placebo treatment…